Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients.

BACKGROUND Aortic stiffness and left ventricular hypertrophy (LVH) are predictors of mortality in hemodialysis (HD) patients. Attenuation of arterial stiffness and regression of LVH had a favorable effect on survival in these patients, but this favorable effect was observed in less than 50% of patients, the rest being resistant to therapeutical interventions. The aim of this study was to analyze the factors associated with this resistance to treatment. METHODS 138 patients on HD were studied during a follow-up survey. From entry until the end of follow up, the changes of aortic pulse wave velocity (PWV) and of LV mass were measured in response to treatment with antihypertensive drugs and erythropoietin, together with measurements of blood chemistry, including high-sensitive C-reactive protein (CRP). Patients with decreased aortic PWV were considered to be responders (N = 68), the others to be nonresponders (N = 70). RESULTS Nonresponders were older (P < 0.05) and had persistently higher systolic blood pressure (BP) and pulse pressure. Responders were treated more frequently with an ACE inhibitor (P < 0.001), and had lower serum CRP (P < 0.01). The baseline PWV, as well as the changes of PWV and LV mass during the follow-up were significantly and independently correlated with serum CRP level (P < 0.001). According to logistic regression after adjustment for age, gender, diabetes, history of CVD, and the nonspecific cardiovascular risk factors, the improvement of aortic stiffness and LV hypertrophy was positively associated with prescription of ACE inhibitor (P < 0.0001), and negatively with the serum CRP level (P < 0.01). CONCLUSION These results indicate that in HD patients, the presence of low-grade inflammation decreases the efficiency of cardiovascular therapeutic interventions and participates in the persistence of cardiovascular hemodynamic overload.

[1]  I. Macdougall,et al.  Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  C. Wanner,et al.  C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  A. Brasier,et al.  Vascular inflammation and the renin-angiotensin system. , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[4]  D. Johns,et al.  Role of superoxide anion in regulating pressor and vascular hypertrophic response to angiotensin II. , 2002, American journal of physiology. Heart and circulatory physiology.

[5]  W. Zoghbi,et al.  Increased Myocardial Gene Expression of Tumor Necrosis Factor-&agr; and Nitric Oxide Synthase-2: A Potential Mechanism for Depressed Myocardial Function in Hibernating Myocardium in Humans , 2002, Circulation.

[6]  M. Phillips,et al.  Angiotensin II as a pro-inflammatory mediator. , 2002, Current opinion in investigational drugs.

[7]  E. DeLong,et al.  Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. , 2002, JAMA.

[8]  K. Iseki,et al.  Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. , 2002, Kidney international.

[9]  Cynthia A. Carnes,et al.  C-Reactive Protein Elevation in Patients With Atrial Arrhythmias: Inflammatory Mechanisms and Persistence of Atrial Fibrillation , 2001, Circulation.

[10]  H. Schmidt,et al.  Upregulation of the vascular NAD(P)H-oxidase isoforms Nox1 and Nox4 by the renin-angiotensin system in vitro and in vivo. , 2001, Free radical biology & medicine.

[11]  J. Blacher,et al.  Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. , 2001, Journal of the American Society of Nephrology : JASN.

[12]  M. Emoto,et al.  Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. , 2001, Journal of the American Society of Nephrology : JASN.

[13]  M. Hori,et al.  C-Reactive Protein Is an Independent Predictor of the Rate of Increase in Early Carotid Atherosclerosis , 2001, Circulation.

[14]  M. Kinoshita,et al.  Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. , 2001, Journal of the American College of Cardiology.

[15]  P. Ducimetiere,et al.  Aortic Stiffness Is an Independent Predictor of All-Cause and Cardiovascular Mortality in Hypertensive Patients , 2001, Hypertension.

[16]  J. Blacher,et al.  Impact of Aortic Stiffness Attenuation on Survival of Patients in End-Stage Renal Failure , 2001, Circulation.

[17]  J. Palmblad,et al.  Do ACE‐inhibitors suppress tumour necrosis factor‐α production in advanced chronic renal failure? , 1999, Journal of internal medicine.

[18]  J. Blacher,et al.  Impact of aortic stiffness on survival in end-stage renal disease. , 1999, Circulation.

[19]  G. London,et al.  Pressure-overload cardiomyopathy in end-stage renal disease , 1999 .

[20]  C. Wanner,et al.  Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. , 1999, Kidney international.

[21]  D. Levy,et al.  Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. , 1998, Circulation.

[22]  W. Owen,et al.  C-reactive protein as an outcome predictor for maintenance hemodialysis patients. , 1998, Kidney international.

[23]  P. Ridker,et al.  Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. , 1998, Circulation.

[24]  J. Satoh,et al.  Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-α in vitro and in vivo , 1997 .

[25]  M. Safar,et al.  Cardiac and arterial interactions in end-stage renal disease. , 1996, Kidney international.

[26]  M. Nauck,et al.  Ca2+-channel blockers modulate the expression of interleukin-6 and interleukin-8 genes in human vascular smooth muscle cells , 1995 .

[27]  C. Dinarello,et al.  Angiotensin-converting-enzyme inhibitors suppress synthesis of tumour necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. , 1995, Cytokine.

[28]  David C. Murray,et al.  Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. , 1995, Kidney international.

[29]  M. Safar,et al.  Cardiac Hypertrophy, Aortic Compliance, Peripheral Resistance, and Wave Reflection in End‐Stage Renal Disease: Comparative Effects of ACE Inhibition and Calcium Channel Blockade , 1994, Circulation.

[30]  M. Safar,et al.  Salt and water retention and calcium blockade in uremia. , 1990, Circulation.

[31]  A. Sniderman,et al.  Impact of left ventricular hypertrophy on survival in end-stage renal disease. , 1989, Kidney international.

[32]  N Reichek,et al.  Echocardiographic Determination of Left Ventricular Mass in Man: Anatomic Validation of the Method , 1977, Circulation.